Latest News for: stat3

Edit

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy ...

Nasdaq Globe Newswire 04 Nov 2021
KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule ...
Edit

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for ...

Tyler Morning Telegraph 04 Nov 2021
Long considered an “undruggable” target, STAT3 hyperactivation is prominent in numerous liquid and solid tumors ... “We will also profile our lead STAT3 degrader, KT-333, which is nearing entry into the clinic in a Phase 1 trial in liquid and solid tumors, and highlight the preclinical activity of STAT3 degraders in STAT3-dependent T cell lymphomas.”.
Edit

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting (Kymera Therapeutics Inc)

Public Technologies 04 Nov 2021
STAT3 is a transcription factor ... "We will also profile our lead STAT3 degrader, KT-333, which is nearing entry into the clinic in a Phase 1 trial in liquid and solid tumors, and highlight the preclinical activity of STAT3 degraders in STAT3-dependent T cell lymphomas.".
Edit

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 ...

Nasdaq Globe Newswire 21 Sep 2021
New patent covers compound and composition and methods of use for. CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO) ... .
Edit

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform (Scopus Biopharma Inc)

Public Technologies 21 Sep 2021
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform ... CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO) ... The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors.
Edit

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant ...

Nasdaq Globe Newswire 12 Jul 2021
Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation ... .
Edit

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum (Kymera Therapeutics Inc)

Public Technologies 12 Jul 2021
Data demonstrate Kymera's ability to degrade mutant and wild-type STAT3, atraditionally 'undruggable' target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation ... Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL).
Edit

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity ...

Tyler Morning Telegraph 12 Jul 2021
Kymera has discovered a series of potent and selective STAT3 degraders with activity against both wild-type and clinically-relevant mutant forms of STAT3.STAT3 degraders result in growth arrest and increased cell death of ALK-positive ALCL, as well as STAT3-mutant NK/T-cell ...
Edit

Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers (Form 8-K) (Bio-Path Holdings Inc)

Public Technologies 22 Jun 2021
Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers ... 11,041,153) is titled 'P-Ethoxy Nucleic Acids for STAT3 Inhibition.' ... About Signal Transducer and Activator of Transcription 3 (STAT3). STAT3 is aberrantly active in cancer cells.
Edit

Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society ...

Nasdaq Globe Newswire 07 Dec 2020
... of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021.
Edit

Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd ...

Tyler Morning Telegraph 07 Dec 2020
KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021 ... STAT3 Program.
×